CHAIRES et al v. NOVO NORDISK INC. et al

Track this case

Case overview

Case Number:

3:17-cv-00699

Court:

New Jersey

Nature of Suit:

Racketeer/Corrupt Organization

Multi Party Litigation:

Class Action

Judge:

Zahid N. Quraishi

Firms

Companies

Sectors & Industries:

May 26, 2023
Lilly To Pay $13M, Cap Insulin Cost In Deal Worth Up To $500M

Insulin buyers asked a New Jersey federal judge Friday to greenlight a class settlement with Eli Lilly & Co. resolving claims it schemed to drive up insulin drug prices, a deal that includes $13.5 million cash and insulin price caps which plaintiffs' lawyers value at $500 million over four years.
July 12, 2021
Insulin Drug Makers Shed Antitrust Claims In MDL

Novo Nordisk Inc., CVS Health Corp. and other drugmakers and pharmacy benefit managers partially secured their bid to escape claims, at least for now, that they colluded to drive up insulin drug prices after a New Jersey federal judge said allegations that direct buyers paid inflated prices weren't enough to support the buyers' antitrust claim.
June 14, 2021
Insulin Makers Blast Patients' 3rd Bid For RICO Claims

Drugmakers Novo Nordisk, Sanofi-Aventis and Eli Lilly and Co. have urged a New Jersey federal judge to nix state racketeering claims filed by diabetics over allegedly excessive insulin prices for the same reason the court previously tossed the federal versions: the consumers didn't buy the medication directly from the companies.
September 23, 2020
3 Firms Win Lead Counsel Roles In Insulin Price-Fixing MDL

A New Jersey federal judge agreed Tuesday to give lead interim counsel roles to attorneys Dianne M. Nast of NastLaw LLC, Michael L. Roberts of Roberts Law Firm PA and Don Barrett of Barrett Law Group PA in antitrust litigation accusing Eli Lilly, Novo Nordisk and Sanofi-Aventis of scheming to drive up insulin drug prices.
June 09, 2020
Insulin Wholesalers Want Consumers To Get Out Of Their Way

A clash between drug wholesalers and insulin users suing manufacturers Eli Lilly, Novo Nordisk and Sanofi-Aventis in New Jersey federal court over alleged fraudulent pricing escalated Monday after two wholesale companies fired off against the consumers' request to pause discovery in the companies' part of the class action.
May 14, 2020
No Bellwether For Diabetics In Insulin Case Despite Virus Risk

Diabetics prepping their sprawling case over insulin prices for a 2022 trial have lost their bid to funnel their claims through a bellwether strategy, although counsel for the patients said they're not giving up yet.
April 29, 2020
Virus-Wary Diabetics Urge Bellwether Trials Over Insulin Costs

Dozens of diabetics leading a class action against top insulin manufacturers Eli Lilly, Novo Nordisk and Sanofi-Aventis over the cost of the medicine fired off a letter to the court Wednesday defending their proposal to send smaller groups of patients to trial first to limit COVID-19 exposure.
February 20, 2020
Patients Can't Revive RICO Claims Against Insulin Makers

Diabetes patients fell short Thursday in their renewed bid to pursue Racketeer Influenced and Corrupt Organizations Act claims against Novo Nordisk, Sanofi-Aventis and Eli Lilly and Co. for allegedly causing them to overpay for insulin medication after a New Jersey federal judge said the consumers could not seek an injunction under the statute.
February 15, 2019
Insulin Giants Beat RICO Claims Brought By Patients

A proposed class of diabetes patients who say three major insulin manufacturers caused them to overpay for the medication can't pursue Racketeer Influenced and Corrupt Organizations Act claims against the drugmakers, a New Jersey federal judge said Friday, because the consumers didn't buy the drugs directly from the companies.
January 17, 2019
Insulin Patients Impacted By Drug-Pricing Scheme, Court Told

A class of diabetes patients alleging the three top insulin manufacturers colluded to drive up medicine prices for the uninsured and underinsured told a New Jersey federal judge Thursday they have standing to file a racketeering claim because they're the only ones in the supply chain injured by the practice.